Market Overview

Robbins Arroyo LLP: Officers and Directors of Nevro Corp. (NVRO) Breached Their Fiduciary Duties According to Shareholder Lawsuit


Shareholder rights law firm Robbins
Arroyo LLP
announces that purchasers of Nevro Corp. (NYSE:NVRO)
have filed a shareholder lawsuit against the company's officers and
directors for breaches of their fiduciary duties from January 8, 2016
through the present. Nevro is a medical device company that provides
products for patients suffering from chronic pain in the United States
and internationally. Nevro's principal products are its HF10 therapies
delivered by its Senza I and Senza II spinal cord stimulation systems.

View this information on the law firm's Shareholder Rights Blog:

Nevro Accused of Scheming to Steal Trade Secrets

According to the complaint, Nevro is engaged in several patent disputes
with Boston Scientific Corp. relating to Nevro's HF10 therapies and the
Senza systems. Boston Scientific contends that Nevro has stolen trade
secrets, tortuously interfered with its contracts, and hired former
Boston Scientific employees to obtain Boston Scientific's trade secrets.
Then, in May 2018, Nevro reported disappointing first quarter 2018
financial results, citing an increase in quarterly operating expenses.
In July 2018, several analysts downgraded the company's stock because
the patent litigation had become a "key risk." That same month, a
tentative ruling in the patent litigation invalidated five of the
patents related to Nevro's HF10 therapy and Senza systems. Since April,
Nevro's stock has lost over half of its value, closing at only $41.60
per share on November 7, 2018.

Nevro Shareholders Have Legal Options

Concerned shareholders who would like more information about their
rights and potential remedies can contact attorney Leonid Kandinov at
(800) 350-6003,,
or via the shareholder
information form
on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder
rights law. The firm represents individual and institutional investors
in shareholder derivative and securities class action lawsuits, and has
helped its clients realize more than $1 billion of value for themselves
and the companies in which they have invested. Sign up for our FREE
portfolio monitoring service, Stock

Attorney Advertising. Past results do not guarantee a similar outcome.

View Comments and Join the Discussion!